Author

P. A. Newbury

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

A. I. Doseff· 1 shared B. Chen· 1 shared E. Chekalin· 1 shared K. A. Gallo· 1 shared R. R. Neubig· 1 shared S. A. Misek· 1 shared S. Paithankar· 1 shared

Activity by Year

2020-2020 · peak 1/yr

Co-Author Collaboration Network

7 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. I. Doseff

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivMar 25, 2020

Ibrutinib blocks YAP1 activation and reverses BRAFi resistance in melanoma cells

S. A. Misek, P. A. Newbury, E. Chekalin…·R. R. Neubig

This study identifies ibrutinib as a drug that reverses BRAFi resistance in melanoma by inhibiting YAP1 and acting through SRC kinase off-target effects, not BTK.

DOI 10.1124/molpharm.121.000331

humanbulk RNA-seq

𝕏 PostBluesky